DK1278540T3 - Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose - Google Patents

Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose

Info

Publication number
DK1278540T3
DK1278540T3 DK01945064T DK01945064T DK1278540T3 DK 1278540 T3 DK1278540 T3 DK 1278540T3 DK 01945064 T DK01945064 T DK 01945064T DK 01945064 T DK01945064 T DK 01945064T DK 1278540 T3 DK1278540 T3 DK 1278540T3
Authority
DK
Denmark
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
Prior art date
Application number
DK01945064T
Other languages
Danish (da)
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Serono Lab
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab, Inst Nat Sante Rech Med filed Critical Serono Lab
Application granted granted Critical
Publication of DK1278540T3 publication Critical patent/DK1278540T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK01945064T 2000-05-05 2001-04-30 Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose DK1278540T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
DK1278540T3 true DK1278540T3 (da) 2008-07-21

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01945064T DK1278540T3 (da) 2000-05-05 2001-04-30 Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose

Country Status (32)

Country Link
US (1) US20040076628A1 (cs)
EP (1) EP1278540B1 (cs)
JP (1) JP5122053B2 (cs)
KR (2) KR20030016254A (cs)
CN (2) CN1250286C (cs)
AR (1) AR035640A1 (cs)
AT (1) ATE395075T1 (cs)
AU (2) AU2001267390B2 (cs)
BG (1) BG65881B1 (cs)
BR (1) BRPI0110506B8 (cs)
CA (1) CA2407895C (cs)
CY (1) CY1110385T1 (cs)
CZ (1) CZ300792B6 (cs)
DE (1) DE60134009D1 (cs)
DK (1) DK1278540T3 (cs)
EA (2) EA005410B1 (cs)
EE (1) EE05056B1 (cs)
ES (1) ES2305082T3 (cs)
HR (1) HRP20020828A2 (cs)
HU (1) HU229375B1 (cs)
IL (2) IL152567A0 (cs)
ME (1) ME00554B (cs)
MX (1) MXPA02010895A (cs)
NO (1) NO329821B1 (cs)
PL (1) PL209371B1 (cs)
PT (1) PT1278540E (cs)
RS (1) RS50926B (cs)
SI (1) SI1278540T1 (cs)
SK (1) SK287761B6 (cs)
UA (2) UA87658C2 (cs)
WO (1) WO2001085201A2 (cs)
ZA (1) ZA200208228B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120011898A (ko) * 2000-02-10 2012-02-08 아보트 러보러터리즈 사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법
ES2295332T3 (es) * 2001-01-29 2008-04-16 Laboratoires Serono Sa Uso de inhibidores de il-18 para el tratamiento y/o prevencion de cardiopatias.
US7655616B2 (en) * 2001-05-25 2010-02-02 Ares Trading S.A. Use of IL-18 inhibitors for treating head injuries
US6797727B2 (en) * 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
CA2478855C (en) 2002-03-22 2013-12-17 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
AU2004219917B2 (en) * 2003-03-11 2008-01-31 Merck Serono Sa Expression vectors comprising the mCMV IE2 promoter
ES2384241T3 (es) 2003-05-13 2012-07-02 Merck Serono Sa Variantes activas de la proteína que fija IL-18 y usos médicos de las mismas
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP2007532617A (ja) * 2004-04-15 2007-11-15 アテラ バイオテクノロジーズ エービー アテローム血栓症およびプラーク破壊を予防するためのアネキシンｖ
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
CA2610804C (en) 2005-06-10 2013-11-19 Ares Trading S.A. Process for the purification of il-18 binding protein
CN103080132B (zh) 2010-08-25 2016-06-08 弗·哈夫曼-拉罗切有限公司 抗il-18r1的抗体及其用途
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
EP3041864B1 (en) 2013-09-05 2021-07-21 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein

Also Published As

Publication number Publication date
NO20025307L (no) 2002-12-18
JP2003532685A (ja) 2003-11-05
AR035640A1 (es) 2004-06-23
US20040076628A1 (en) 2004-04-22
EP1278540B1 (en) 2008-05-14
EA200201175A1 (ru) 2003-04-24
HU229375B1 (en) 2013-11-28
HUP0301991A2 (hu) 2003-09-29
BG65881B1 (bg) 2010-04-30
KR20030016254A (ko) 2003-02-26
CN1841066B (zh) 2012-08-29
CZ300792B6 (cs) 2009-08-12
EA200401183A1 (ru) 2004-12-30
HRP20020828A2 (en) 2004-12-31
WO2001085201A2 (en) 2001-11-15
SK15562002A3 (sk) 2003-05-02
MEP64008A (en) 2011-12-20
IL152567A (en) 2010-12-30
EA007014B1 (ru) 2006-06-30
CN1434722A (zh) 2003-08-06
DE60134009D1 (de) 2008-06-26
KR20070073989A (ko) 2007-07-10
RS50926B (sr) 2010-08-31
CN1841066A (zh) 2006-10-04
ZA200208228B (en) 2005-07-27
PL365697A1 (en) 2005-01-10
PT1278540E (pt) 2008-07-03
NO20025307D0 (no) 2002-11-05
SK287761B6 (en) 2011-09-05
EP1278540A2 (en) 2003-01-29
UA78492C2 (en) 2007-04-10
ME00554B (me) 2012-03-20
IL152567A0 (en) 2003-05-29
CA2407895C (en) 2012-12-18
HK1055681A1 (en) 2004-01-21
KR100798545B1 (ko) 2008-01-28
ATE395075T1 (de) 2008-05-15
SI1278540T1 (sl) 2008-10-31
CN1250286C (zh) 2006-04-12
BRPI0110506B8 (pt) 2021-05-25
BRPI0110506B1 (pt) 2015-05-19
AU6739001A (en) 2001-11-20
BR0110506A (pt) 2003-04-01
YU82602A (sh) 2006-01-16
HUP0301991A3 (en) 2006-11-28
ES2305082T3 (es) 2008-11-01
JP5122053B2 (ja) 2013-01-16
CY1110385T1 (el) 2015-04-29
AU2001267390B2 (en) 2005-09-22
EA005410B1 (ru) 2005-02-24
WO2001085201A3 (en) 2002-05-10
NO329821B1 (no) 2010-12-27
EE05056B1 (et) 2008-08-15
CZ20023644A3 (cs) 2003-03-12
MXPA02010895A (es) 2003-03-27
EE200200620A (et) 2004-06-15
UA87658C2 (uk) 2009-08-10
PL209371B1 (pl) 2011-08-31
CA2407895A1 (en) 2001-11-15
BG107218A (bg) 2003-06-30
HK1094909A1 (en) 2007-04-13

Similar Documents

Publication Publication Date Title
DK1278540T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK1506041T3 (da) Inbandronsyre til behandling og forebyggelse af osteoporose
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
IS6700A (is) Meðferðarblanda CETP hindra og atórvastatíns
NO20020343D0 (no) Kaspase-inhibitorer og anvendelse derav
NO20015274D0 (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
DK1282719T3 (da) Fremgangsmåde til fremstilling af dihydroxyestere og derivater deraf
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
IS7003A (is) Arómatisk súlfonhýdroxýamöt og notkun þeirra til tálmunar próteasa
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
DE60223540D1 (de) Mundschutz und mundschutzfolie
DK1456377T3 (da) Syn3-sammensætninger og fremgangsmåder
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
NO20011176D0 (no) FremgangsmÕte og anordning ved mær
DK1307761T3 (da) Fremgangsmåde til retningsbestemmelse og bestemmelsesapparat
IT1315029B1 (it) Metodo e linea per la laminazione di rotaie o altre sezioni
DK1105101T3 (da) Fremgangsmåder og præparater til behandling af intracellulære infektioner